GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

nelfinavir   Click here for help

GtoPdb Ligand ID: 11090

Synonyms: AG-1343 | AG1343 | Viracept®
Approved drug PDB Ligand
nelfinavir is an approved drug (FDA (1997))
Compound class: Synthetic organic
Comment: Nelfinavir is an oral antiretroviral drug. It inhibits human immunodeficiency virus (HIV) protease.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 12
Topological polar surface area 127.2
Molecular weight 567.31
XLogP 6
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O[C@@H]([C@@H](NC(=O)c1cccc(c1C)O)CSc1ccccc1)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
Isomeric SMILES O[C@@H]([C@@H](NC(=O)c1cccc(c1C)O)CSc1ccccc1)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
InChI InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1
InChI Key QAGYKUNXZHXKMR-HKWSIXNMSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Nelfinavir is used to treat HIV infection, usually in combination with other antiretroviral drugs. EMA marketing authorisation (granted in 1998) was later withdrawn. Nelfinavir has anti-cancer activity and radiosensitizing effects and has advanced to clinical trials for solid tumours and hematological malignancies. It is also being repositioned for COVID-19, having demonstrated antiviral activity against SARS-CoV-2 [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03256916 Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix Phase 3 Interventional Tata Memorial Hospital
NCT02188537 Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma Phase 2 Interventional Swiss Group for Clinical Cancer Research
External links Click here for help